Increased Expression of the Glucose Transporter Type 1 Gene Is Associated With Worse Overall Survival in Resected Pancreatic Adenocarcinoma
- PMID: 26692443
- PMCID: PMC4912950
- DOI: 10.1097/MPA.0000000000000580
Increased Expression of the Glucose Transporter Type 1 Gene Is Associated With Worse Overall Survival in Resected Pancreatic Adenocarcinoma
Abstract
Objectives: There is currently no reliable method to predict the risk of relapse after curative resection of early-stage pancreatic adenocarcinoma. Increased glucose metabolism observed on F-fluorodeoxyglucose positron emission tomography (PET) by malignant cells, the Warburg effect, is a well-known characteristic of the malignant phenotype. We investigated the role of glucose transporter type 1 (GLUT-1) gene expression, a glucose cell plasma membrane transporter, in early-stage pancreatic cancer.
Methods: Associations between GLUT-1 gene expression with PET maximum standardized uptake values and histologic grade were investigated in early-stage pancreatic adenocarcinoma patients. Multivariate analysis was conducted to determine predictors of prognosis. Cox proportional hazard model was used for survival analysis.
Results: Sixty-three patients had GLUT-1 gene analysis performed, and 50 patients had both GLUT-1 analysis and PET scan. Patients with high GLUT-1 gene expression had a decreased overall survival by univariate analysis using Cox proportional hazard model (hazard ratio, 2.82; P = 0.001) and remained significant on multivariate analysis (hazard ratio, 2.54; P = 0.03). There was no correlation of GLUT-1 gene expression with histologic grade or PET maximum standardized uptake values.
Conclusions: Increased GLUT-1 gene expression was associated with a decreased overall survival in pancreatic adenocarcinoma. This supports increased GLUT-1 gene expression as a potential prognostic marker in resected pancreatic adenocarcinoma.
Conflict of interest statement
The authors have no conflicts of interest to disclose.
Figures



Similar articles
-
Preoperative High Maximum Standardized Uptake Value in Association with Glucose Transporter 1 Predicts Poor Prognosis in Pancreatic Cancer.Ann Surg Oncol. 2017 Jul;24(7):2040-2046. doi: 10.1245/s10434-017-5799-1. Epub 2017 Feb 8. Ann Surg Oncol. 2017. PMID: 28180987
-
Comparing prognostic factors of Glut-1 expression and maximum standardized uptake value by FDG-PET in patients with resectable pancreatic cancer.Pancreatology. 2020 Sep;20(6):1205-1212. doi: 10.1016/j.pan.2020.07.407. Epub 2020 Aug 3. Pancreatology. 2020. PMID: 32819845
-
Prognostic value of dual-point fluorine-18 fluorodeoxyglucose PET imaging, partial volume correction and glucose transporter-1 expression in resected nonsmall cell lung cancer patients.Nucl Med Commun. 2020 Jan;41(1):48-57. doi: 10.1097/MNM.0000000000001118. Nucl Med Commun. 2020. PMID: 31764590
-
Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in gastric carcinoma: relation to histological subtypes, depth of tumor invasion, and glucose transporter-1 expression.Ann Nucl Med. 2006 Nov;20(9):597-604. doi: 10.1007/BF02984657. Ann Nucl Med. 2006. PMID: 17294670
-
Prognostic Significance of 18F-FDG PET/CT Metabolic Parameters and Tumor Galectin-1 Expression in Patients With Surgically Resected Lung Adenocarcinoma.Clin Lung Cancer. 2019 Nov;20(6):420-428. doi: 10.1016/j.cllc.2019.04.002. Epub 2019 May 17. Clin Lung Cancer. 2019. PMID: 31300363
Cited by
-
GLUT-1 may predict metastases and death in patients with locally advanced rectal cancer.Front Oncol. 2023 Mar 9;13:1094480. doi: 10.3389/fonc.2023.1094480. eCollection 2023. Front Oncol. 2023. PMID: 36968998 Free PMC article.
-
Roles of GLUT-1 and HK-II expression in the biological behavior of head and neck cancer.Oncotarget. 2019 Apr 30;10(32):3066-3083. doi: 10.18632/oncotarget.24684. eCollection 2019 Apr 30. Oncotarget. 2019. PMID: 31105886 Free PMC article.
-
Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies.Cancer Cell. 2017 Mar 13;31(3):311-325. doi: 10.1016/j.ccell.2017.02.008. Cancer Cell. 2017. PMID: 28292435 Free PMC article. Review.
-
Power of two: combination of therapeutic approaches involving glucose transporter (GLUT) inhibitors to combat cancer.Biochim Biophys Acta Rev Cancer. 2020 Dec;1874(2):188457. doi: 10.1016/j.bbcan.2020.188457. Epub 2020 Oct 21. Biochim Biophys Acta Rev Cancer. 2020. PMID: 33096154 Free PMC article. Review.
-
Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma.Int J Mol Sci. 2017 Mar 20;18(3):667. doi: 10.3390/ijms18030667. Int J Mol Sci. 2017. PMID: 28335509 Free PMC article. Review.
References
-
- Warburg O. On the origin of cancer cells. Science. 1956;123:309–314. - PubMed
-
- Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med. 1993;34:414–419. - PubMed
-
- Macheda M, Rogers S, Best J. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol. 2005;202:654–662. - PubMed
-
- Cornford EM, Hyman S, Swartz BE. The human brain GLUT1 glucose transporter: ultrastructural localization to the blood-brain barrier endothelia. J Cereb Blood Flow Metab. 1994;14:106–112. - PubMed
-
- Kayano T, Burant CF, Fukumoto H, et al. Human facilitative glucose transporters. Isolation, functional characterization, and gene localization of cDNAs encoding an isoform (GLUT5) expressed in small intestine, kidney, muscle, and adipose tissue and an unusual glucose transporter pseudogene-like sequence (GLUT6) J Biol Chem. 1990;265:13276–13282. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous